Previous 10 | Next 10 |
home / stock / nonof / nonof news
2024-04-18 12:40:00 ET Summary Laughing Water Capital is a concentrated, long biased investment partnership open to accredited investors. Our interests are fully aligned with our partners as nearly all of our personal wealth is invested in our strategy. Laughing Water Capital retu...
2024-04-17 07:04:07 ET More on Eli Lilly Eli Lilly: Three Threats To Its Huge Rally Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets GLP-1s ...
2024-04-16 14:16:55 ET Summary Just as the "Magnificent 7" stocks lead returns and headlines in US markets, an 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. Here I run a head-to-head comparison using the Magnificent 7 as a proxy for the Invesco QQQ ET...
2024-04-12 12:02:53 ET More on AbbVie, Biogen, etc. AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% Novo Nordisk: The Moat Won't Last Forever AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision No link between weight...
2024-04-12 07:05:43 ET More on Eli Lilly, Novo Nordisk, etc. Novo Nordisk: The Moat Won't Last Forever Eli Lilly: Three Threats To Its Huge Rally Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data Roche, Eli Lilly gain ...
2024-04-10 12:30:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We believe internation...
2024-04-10 07:34:44 ET More on Ginkgo Bioworks Ginkgo Bioworks: Multiple Red Flags Ginkgo Bioworks: More Awful Revenue Guidance Ginkgo Bioworks Holdings, Inc. 2023 Q4 - Results - Earnings Call Presentation Ginkgo Bioworks acquires cell therapy assets from Mod...
2024-04-09 13:06:07 ET More on Eli Lilly Eli Lilly: Three Threats To Its Huge Rally Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets EMA to ...
2024-04-09 11:30:10 ET Summary Today, we take a look at Novo Nordisk A/S, whose growth is being powered by Wegovy and Ozempic. The GLP-1 market is projected by some to grow to $100 billion by 2030 and Novo Nordisk is currently the preeminent player in this burgeoning space. Ho...
2024-04-03 07:01:03 ET More on Novo Nordisk Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified Novo Nordisk, A Very Healthy Pharma Stalwart CVS, Elevance Health to c...
News, Short Squeeze, Breakout and More Instantly...
Novo-Nordisk A/S Company Name:
NONOF Stock Symbol:
OTCMKTS Market:
Patients using Novo Nordisk’s (NYSE:NVO) (OTC:NONOF) obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over...
A landmark moment in France’s health industry is expected as President Emmanuel Macron is set to announce a significant $2.3 billion investme...
New side effects of the ‘miracle’ weight loss drug Ozempic are emerging, causing concern among patients and healthcare profes...